Contact Us
  • This field is for validation purposes and should be left unchanged.

National Heart, Lung, and Blood Institute (NHLBI)

A. Biomedical technologies (medical devices, instruments, pharmaceuticals, drugs, therapeutics, vaccines, diagnostics and biologics) for heart, lung, blood, and sleep related diseases and disorders requiring Federal regulatory approval (FDA) or clearance to be commercialized.
B. Small and large animal testing of products of tissue engineering and regenerative medicine, drugs, medical devices, therapeutics, and biologics and studies involving in vivo animal experiments for heart, lung, blood, and sleep related diseases and disorders.
C. Clinical trials and other experiments involving human subjects for heart, lung, blood, and sleep related diseases and disorders.
D. Therapeutics (drugs, devices, or biologics) development for heart, lung, blood, and sleep related diseases and disorders.
E. Device development for heart, lung, blood, and sleep related diseases and disorders
F. Diagnostics development for heart, lung, blood, and sleep related diseases and disorders.
G. Investigation of biomarkers and biosignatures of heart, lung, blood, and sleep related diseases and disorders.
H. Technologies to enhance clinical research for heart, lung, blood, and sleep related diseases and disorders.
I. Advanced instrumentation and high throughput tools for biomedical research in heart, lung, blood, and sleep related diseases and disorders.
J. Tools and platforms to improve the dissemination and implementation of evidence-based interventions for heart, lung, blood, and sleep related diseases and disorders.

Contact Us
  • This field is for validation purposes and should be left unchanged.